Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Forum
  • Discovery
  • About Us
    • Our Coverage
    • Team

Initiator Pharma

3.08 SEK

-0.65 %

Less than 1K followers

INIT

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.65 %
+3.01 %
+4.05 %
+4.41 %
-10.98 %
-53.68 %
-47.17 %
-28.80 %
-31.34 %

Initiator Pharma is a biotechnology company developing drug candidates for diseases of the central and peripheral nervous system. The company's main business focus is on the development of drug candidates used in the treatment of erectile dysfunction in men. Initiator Pharma was founded through a spin-off from the company Saniona and is headquartered in Denmark.

Read more
Market cap
210.83M SEK
Turnover
81.61K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
8.5
2026

Interim report Q1'26

29.5
2026

General meeting '26

21.8
2026

Interim report Q2'26

All
Press releases
ShowingAll content types
Press release2/23/2026, 10:56 AM

DNB Carnegie Access: Initiator Pharma: Moving in the right direction – Q4 review

Initiator Pharma
Press release2/20/2026, 3:26 PM

Redeye: Initiator Pharma (Q4 Review): Dosing underway in phase IIa study

Initiator Pharma
Regulatory press release2/20/2026, 7:30 AM

INITIATOR PHARMA: Q4 2025 REPORT

Initiator Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2/18/2026, 2:00 PM

Initiator Pharma granted European patent for pudafensine in Female Sexual Dysfunction, including vulvodynia

Initiator Pharma
Press release12/23/2025, 2:27 PM

DNB Carnegie Access: Initiator Pharma: Vulvodynia study enrolment has started

Initiator Pharma
Press release12/23/2025, 7:31 AM

Initiator Pharma to attend J.P. Morgan Healthcare Conference in San Francisco

Initiator Pharma
Press release12/23/2025, 7:30 AM

Initiator Pharma initiates patient enrollment in Phase IIa vulvodynia study

Initiator Pharma
Press release11/24/2025, 7:56 AM

DNB Carnegie Access: Initiator Pharma: Advancing in vulvodynia – Q3 review

Initiator Pharma
Press release11/21/2025, 3:03 PM

Redeye: Initiator Pharma (Q3 review) - Back in the clinic

Initiator Pharma
Regulatory press release11/21/2025, 8:55 AM

Correction: INITIATOR PHARMA: Q3 2025 REPORT

Initiator Pharma
Regulatory press release11/21/2025, 7:30 AM

INITIATOR PHARMA: Q3 2025 REPORT

Initiator Pharma
Press release11/18/2025, 1:03 PM

BioStock: Video from Initiator Pharma’s presentation at the BioStock Life Science Summit 2025

Initiator Pharma
Press release11/3/2025, 7:30 AM

Initiator Pharma receives UK CTA approval to initiate Phase 2a study in vulvodynia

Initiator Pharma
Press release9/25/2025, 9:49 AM

BioStock: Video from Initiator Pharma’s live interview at BioStock Investing in Life Science – From Seed to Success

Initiator Pharma
Press release9/8/2025, 7:30 AM

Initiator Pharma to present at Nordic Women’s Health Hub 2025

Initiator Pharma
Press release9/3/2025, 11:15 AM

Initiator Pharma applies to initiate Phase 2a study in vulvodynia

Initiator Pharma
Press release8/25/2025, 8:58 AM

DNB Carnegie Access: Initiator Pharma: Study initiation approaching – Q2 review

Initiator Pharma
Press release8/22/2025, 10:57 AM

Redeye: Initiator Pharma Q2 - Financed to explore vulvodynia

Initiator Pharma
Regulatory press release8/22/2025, 6:30 AM

INITIATOR PHARMA: Q2 2025 REPORT

Initiator Pharma
Regulatory press release7/16/2025, 1:45 PM

Initiator Pharma carries out a directed new share issue to guarantors

Initiator Pharma
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.